59 trends tracked about this subject — the full history, oldest to newest below.
Researchers screening 6,000 drugs have identified that common GLP-1 medications may possess significant anti-aging properties.
Concerns are rising over potential muscle loss and increased frailty in older adults using GLP-1 weight loss medications.
Patients are facing restricted access to GLP-1 drugs like Ozempic and Wegovy due to high costs and restrictive insurance policies.
Logistics giants are aggressively expanding cold storage infrastructure to accommodate a surge in GLP-1 drug demand and a broader healthcare boom.
Australian regulators and medical advisors warn of a rare but severe risk of vision loss linked to GLP-1 weight-loss medications including Ozempic.
Pharmacists and health experts are urging GLP-1 weight loss medication users to prioritize specific nutritional strategies to mitigate side effects.
A surge in fiber consumption is trending as medical experts highlight its natural ability to lower LDL cholesterol and support GLP-1 medications.
New research suggests a link between GLP-1 weight-loss medications and an increased risk of hair loss, though the occurrence is described as rare.
New research links GLP-1 weight-loss medications like Ozempic and Mounjaro to an increased risk of hair loss in patients.
GLP-1 weight-loss medications are seeing a surge in adoption among adolescents and children globally, shifting treatment patterns for youth obesity.
A new economic study indicates that GLP-1 weight loss drugs are linked to a 17% decrease in worker sick leave, suggesting a potential boost to labor productivity.
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of deceptive and misleading advertising regarding GLP-1 weight-loss drugs.
Novo Nordisk has launched a legal offensive against Eli Lilly, alleging that the competitor's GLP-1 weight-loss drug advertising is deceptive.
A Georgia woman has joined a growing lawsuit connecting popular GLP-1 weight loss drugs to a rare and blinding eye condition.
Emerging trends in GLP-1 medications highlight an expansion beyond weight loss, including therapeutic retreats and rising use among young adults.
Rapid adoption of GLP-1 weight-loss drugs is sparking new debates over adolescent use, compounded safety, and the social stigma of medication.
Health experts and trainers are advocating for targeted strength training for adults over 50 to combat age-related muscle loss and improve longevity.
Emerging research suggests GLP-1 receptor agonists may provide a promising treatment for binge eating disorder and emotional eating symptoms.
A US woman has welcomed a baby boy after mistaking her pregnancy symptoms for side effects of GLP-1 medications.
A 54-year-old woman's emergency room hospitalization after a GLP-1 overdose highlights rising public safety concerns.
New analysis suggests that weight loss achieved through obesity drugs does not necessarily translate into improved mental health or better job prospects.
Medical research is exploring the intersection of GLP-1 receptor agonists and oncology, triggering debate over their potential role in cancer treatment.
Recent studies examine a low-protein longevity diet linked to healthier aging, fat reduction, and natural GLP-1 boosts in mice.
Insurance executives and employers are redefining access to GLP-1 weight-loss medications amid shifting coverage trends and affordability challenges.
A new oral GLP-1 receptor agonist is emerging as a potent weight-loss alternative, outperforming oral Ozempic in recent clinical trials.
Medical professionals are warning GLP-1 medication users about 'Ozempic feet,' a surprising new side effect emerging alongside rapid weight loss.
Amy Schumer is drawing attention for sharing photos of her C-section scar and discussing her weight loss journey during July 4th celebrations.
Novo Nordisk and Vivani are partnering to develop a long-acting semaglutide implant designed to improve weight loss adherence for up to a year.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Ozempic’s skin effects are sparking a wave of cosmetic concern across Gen X.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Social media discourse and emerging clinical research are converging on the long-term potential of GLP-1 agonists beyond weight management.
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Peptide therapy has emerged as a major wellness trend, sparking concerns over the safety and regulatory status of products in a rapidly growing market.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
GLP-1 weight‑loss drugs spark a wave of research, clinical guidance and market buzz as they expand beyond obesity treatment.
Medicare initiates a pilot program providing coverage for GLP-1 weight-loss medications beginning July 1, 2026.
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Research into GLP-1 receptor agonists is shifting focus from weight management to potential longevity benefits and broader therapeutic applications.
New research highlights concerns over the potential misuse of GLP-1 receptor agonist medications among individuals diagnosed with eating disorders.
Oral GLP-1 medications are gaining attention as clinical data emerges regarding their efficacy in weight management and potential to shift treatment paradigms.
Major pharmacy retailers are expanding support services as a new Medicare program launches to reduce costs for GLP-1 weight management medications.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Recent research reveals that individuals using GLP-1 weight-loss medications exhibit a decline in physical activity levels.
16 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
11 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New study data indicates that GLP-1 weight loss medications are associated with a significant reduction in the risk of developing four specific cancer types.
New clinical research presented at ASCO26 suggests a potential link between GLP-1 receptor agonist medications and reduced cancer risk.
New research indicates that patients taking GLP-1 weight loss drugs are reducing their physical activity levels.
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
US employers may halt GLP-1 drug coverage in 2027 amid rising costs and usage spikes